Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04588662 · ClinicalTrials.gov registry record
A Prospective Natural History Study in Uveal Melanoma
A clinical trial of Uveal Melanoma, sponsored by Columbia University.
- Active
- Registry status
- 122
- Enrollment target
- 17
- Study locations
NCT04588662 is a study of Uveal Melanoma that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 122 participants, below the 141-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (13% lower). The trial reports 17 study locations across 5 states.
The verdict
NCT04588662, a study of Uveal Melanoma, is active but no longer recruiting, sponsored by Columbia University.
- ACTIVE NOT RECRUITING
- Registry status
- 122 participants
- Enrollment target
- 17
- Study locations
Study Summary
The overall objective of this proposal is to develop and utilize a multicenter UM registry that will, in a longitudinal fashion, capture prospective data in order to characterize the natural history of UM and provide data that will be used to support the development of novel therapies for this disease. The care of patients with UM requires a multi-disciplinary team of physicians that commonly requires the involvement of both radiation oncology and interventional radiology, and is typically directed by an ophthalmologic oncologist at time of initial diagnosis of primary disease. Overall management is transitioned to a medical oncologist when distant recurrence is identified. In the case that a patient presents with metastasis at the time of diagnosis, a medical oncologist typically directs overall management. The management of surveillance for the development of metastasis following the treatment of primary disease is variable and, if performed at all, is managed by either an ophthalmologic oncologist or medical oncologist. Thus, the successful development of a registry that aims to capture the data regarding the full natural history of UM requires a collaborative effort including leaders from both the UM ophthalmologic oncology and medical oncology fields. To this end, the investigators have built an initial consortium of key ophthalmologic oncology and medical oncology leaders from multiple major UM centers in the United States.
Conditions Studied
Study Locations (17)
Other
- Royal Adelaide Hospital - Adelaide
- Chatswood Eye Specialists - Chatswood
- Royal Victorian Eve and Ear Hospital - East Melbourne
- Western Eye Specialists - Maribyrnong
- Pennington Eye Clinic - North Adelaide
- Perth Retina - Subiaco
- Dr. Conway Private Rooms - Sydney
- St. Vincent's Hospital - Sydney
- Princess Margaret Cancer Center - Toronto
- Erlangen - Erlangen
- Clatterbridge Cancer Centre - Birkenhead
- Mount Vernon Cancer Centre - Northwood
- Sheffield - Sheffield
Massachusetts
- Massachusetts General Hospital - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2021-05-06 |
| Est. Completion | 2026-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04588662
The ClinicalTrials.gov registry entry for NCT04588662 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 141-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (13% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT04588662 reports 17 study locations spanning 5 distinct geographic areas - top geographies include Other, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04588662 about?
NCT04588662 is a clinical study titled "A Prospective Natural History Study in Uveal Melanoma". The overall objective of this proposal is to develop and utilize a multicenter UM registry that will, in a longitudinal fashion, capture prospective data in order to characterize the natural history of UM and provide data that will be used to support the development of novel therapies for this disea...
What is the current status of trial NCT04588662?
This trial is currently active not recruiting. The enrollment target is 122 participants. The study started on 2021-05-06. Estimated completion is 2026-07.
What conditions does trial NCT04588662 study?
This clinical trial studies the following conditions: Uveal Melanoma.
Who is sponsoring clinical trial NCT04588662?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04588662 being conducted?
This trial has 17 study locations across Massachusetts, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
RECRUITING · NA
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.